...
首页> 外文期刊>OncoTargets and therapy >Micro-ribonucleic acid 29b inhibits cell proliferation and invasion and enhances cell apoptosis and?chemotherapy effects of cisplatin via targeting of DNMT3b and AKT3 in prostate cancer
【24h】

Micro-ribonucleic acid 29b inhibits cell proliferation and invasion and enhances cell apoptosis and?chemotherapy effects of cisplatin via targeting of DNMT3b and AKT3 in prostate cancer

机译:微核糖核酸29b通过靶向DNMT3b和AKT3抑制前列腺癌细胞增殖和侵袭并增强细胞凋亡和顺铂化疗作用

获取原文
           

摘要

Background: Micro-ribonucleic acids (miRNAs) are crucial regulators in malignant tumors. miRNA-29b (miR-29b) has been identified as a tumor suppressor in prostate cancer (PCa). However, very few studies have investigated the effects of miR-29b in PCa, especially the mechanism and its association with chemotherapy. Our study aimed to explore the role and mechanism of miR-29b in PCa. Materials and methods: The expression levels of miR-29b were detected in ten clinical PCa specimens and four different PCa cell lines through quantitative real-time polymerase chain reaction. After miR-29b mimics and inhibitors were successfully transfected into LNCaP, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was then used to investigate cell proliferation and cisplatin sensitivity of PCa cells. Cell cycle, cell apoptosis, and cell invasion were detected via flow cytometry, annexin V–fluorescein isothiocyanate labeling, and transwell assay, respectively. Based on bioinformatic methods, Western blot analysis, and dual-luciferase reporter assay, novel target genes of miR-29b were identified. Results: miR-29b was downregulated in PCa tissues compared with matched adjacent nontumor tissues. In the androgen-independent PCa cell line (LNCaP-AI), the expression of miR-29b was much lower than the androgen-dependent PCa cell line (LNCaP). Subsequent studies showed that forced expression of miR-29b inhibited cell proliferation and cell invasion and induced cell apoptosis in PCa. Upregulation of miR-29b also enhanced the chemosensitivity of PCa cells to cisplatin. Moreover, we identified DNMT3b and AKT3 as novel target genes of miR-29b in PCa. Conclusion: Taken together, the results showed that miR-29b plays a tumor-suppressive role in PCa. It inhibits cell biological behavior and enhances the chemotherapy effects of cisplatin through its involvement in epigenetic regulation and PI3K/AKT pathway.
机译:背景:微核糖核酸(miRNA)是恶性肿瘤中的关键调节因子。 miRNA-29b(miR-29b)已被鉴定为前列腺癌(PCa)中的肿瘤抑制因子。但是,很少有研究调查miR-29b在PCa中的作用,特别是其机制及其与化学疗法的关系。我们的研究旨在探讨miR-29b在PCa中的作用和机制。材料和方法:通过定量实时聚合酶链反应,在十个临床PCa标本和四个不同的PCa细胞系中检测到miR-29b的表达水平。将miR-29b模拟物和抑制剂成功转染到LNCaP中后,然后使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四溴甲烷测定法研究PCa细胞的细胞增殖和顺铂敏感性。细胞周期,细胞凋亡和细胞侵袭分别通过流式细胞术,膜联蛋白V-异硫氰酸荧光素标记和transwell检测来检测。基于生物信息学方法,Western印迹分析和双荧光素酶报告基因分析,鉴定了miR-29b的新靶基因。结果:与匹配的相邻非肿瘤组织相比,miR-29b在PCa组织中被下调。在非雄激素依赖性PCa细胞系(LNCaP-AI)中,miR-29b的表达远低于雄激素依赖性PCa细胞系(LNCaP)。随后的研究表明,miR-29b的强制表达抑制PCa中的细胞增殖和侵袭并诱导细胞凋亡。 miR-29b的上调也增强了PCa细胞对顺铂的化学敏感性。此外,我们确定DNMT3b和AKT3为PCa中miR-29b的新型靶基因。结论:综上所述,结果表明miR-29b在PCa中起肿瘤抑制作用。它通过参与表观遗传调控和PI3K / AKT途径来抑制顺铂的细胞生物学行为并增强其化疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号